Hester Biosciences Limited — Board Meeting, 30-01-2025: Outcome of Board Meeting

The Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months period ended 31 December 2024. Standalone revenue from operations stands at ₹628.26 cr, down 4% compared to the previous quarter, while nine-month revenue increased by 14% to ₹2,097.94 cr. Profit after tax for the quarter is ₹44.39 cr, a decline of 31%, but up 13% for the nine months at ₹222.07 cr. Consolidated results reflect a profit after tax of ₹114.08 cr for the quarter, marking an impressive 184% increase compared to the previous year, with nine-month profit up 85% at ₹272.85 cr.